3.2. Pharmacokinetics in Blood Plasma
Initially, the mean concentrations of spermidine, spermine, and putrescine in the plasma and saliva in the placebo intervention of all 12 subjects combined over all time samples were determined as follows: spermidine (plasma) 12.41 ng/mL (SD 1.869), spermine (plasma) 5.102 ng/mL (SD 0.4646), and putrescine (plasma) 7.403 ng/mL (SD 2.130); spermidine (saliva) 236.5 ng/mL (SD 181.5), spermine (saliva) 201.0 ng/mL (SD 76.02), and putrescine (saliva) 4.343 µg/mL. Subsequently, concentrations of spermidine, spermine, and putrescine in plasma and saliva for both the placebo and verum interventions were compared for AUCInterestingly, four of the 12 subjects still had higher AUCFor both study arms, a Friedman test (nonparametric ANOVA) was performed to compare the fasted matutinal spermine plasma levels at 0, 24, 48, 72, and 96 h with each other within the specific study treatment (verum or placebo). Within the placebo treatment, a 